{
  "docId": "019de072-1de2-7119-a555-9ff409e7e548",
  "docSlug": "506aa41f1d83c0fffcc1a747d59c4e2b",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 86 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 35,
  "pageCount": 86,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "other",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide provides a status update on 14 distinct product development or launch initiatives.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-1de2-7119-a555-9ff409e7e548/35",
  "deckHref": "/decks/019de072-1de2-7119-a555-9ff409e7e548",
  "deckJsonHref": "/decks/019de072-1de2-7119-a555-9ff409e7e548.json",
  "deckAnchorHref": "/decks/019de072-1de2-7119-a555-9ff409e7e548#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.72,
        "x": 0.26,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "1. See slide 1 for further information on forward-looking statements. 2. Investigational device exemption. 3. Exclusive licensing agreement with Clearside Biomedical, Inc. 4. In 2019, the Company acquired an exclusive license from Novaliq GmbH...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e67a5a3e-bdd2-42ab-863a-c5153714b03b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.94,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "list",
      "text": "SiHy Daily, Biotrue, LUMIFY, Extended depth of focus lens, enVista, COVD, ClearVisc, StableVisc, XIPERE, Alaway, NOV03, Lucentis biosimilar, Microdose atropine, Myopia control lens, eyeTELLIGENCE agreement.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a076c7da-7c47-45b0-8775-dccd2e9a17db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Pipeline and Portfolio Expansion: Late Stage Development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b1a4c42-c669-4066-a8df-8925c6a65659",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}